AstraZeneca, Ironwood agree US licensing deal for gout treatment

AstraZeneca said it had entered a licensing agreement with Ironwood Pharmaceuticals over exclusive US rights to Zurampic, which is used to treat hyperuricemia associated with uncontrolled gout.

AstraZeneca

9,990.00p

15:45 15/11/24

-2.93%

-302.00p

FTSE 100

8,060.61

15:45 15/11/24

n/a

FTSE 350

4,453.56

15:45 15/11/24

n/a

FTSE All-Share

4,411.85

15:45 15/11/24

n/a

Pharmaceuticals & Biotechnology

19,259.77

15:45 15/11/24

-2.70%

-535.19

Ironwood will get rights to Zurampic and exclusive US rights to the fixed-dose combination of lesinurad and allopurinol.
AstraZeneca said it planned to submit the fixed-dose combination programme for regulatory review in the second half of 2016.

Ironwood will pay AstraZeneca sales-related and other milestone payments of up to $265m and tiered single-digit royalties on product sales.

AstraZeneca will make and supply Zurampic, provide certain support and services to Ironwood and undertake the FDA post-approval commitment on its behalf.

The agreement does not impact AstraZeneca's financial guidance for 2016.